Literature DB >> 28025584

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

M I da Silva Filho1, A Försti1,2, N Weinhold3,4, I Meziane1, C Campo1, S Huhn3, J Nickel3, P Hoffmann5,6, M M Nöthen5,7, K-H Jöckel8, S Landi9, J S Mitchell10, D Johnson11, G J Morgan4, R Houlston10,11, H Goldschmidt3,12, A Jauch13, P Milani14, G Merlini14, D Rowcieno15, P Hawkins15, U Hegenbart3, G Palladini14, A Wechalekar15, S O Schönland3, K Hemminki1,2.   

Abstract

Immunoglobulin light chain (AL) amyloidosis is characterized by tissue deposition of amyloid fibers derived from immunoglobulin light chain. AL amyloidosis and multiple myeloma (MM) originate from monoclonal gammopathy of undetermined significance. We wanted to characterize germline susceptibility to AL amyloidosis using a genome-wide association study (GWAS) on 1229 AL amyloidosis patients from Germany, UK and Italy, and 7526 healthy local controls. For comparison with MM, recent GWAS data on 3790 cases were used. For AL amyloidosis, single nucleotide polymorphisms (SNPs) at 10 loci showed evidence of an association at P<10-5 with homogeneity of results from the 3 sample sets; some of these were previously documented to influence MM risk, including the SNP at the IRF4 binding site. In AL amyloidosis, rs9344 at the splice site of cyclin D1, promoting translocation (11;14), reached the highest significance, P=7.80 × 10-11; the SNP was only marginally significant in MM. SNP rs79419269 close to gene SMARCD3 involved in chromatin remodeling was also significant (P=5.2 × 10-8). These data provide evidence for common genetic susceptibility to AL amyloidosis and MM. Cyclin D1 is a more prominent driver in AL amyloidosis than in MM, but the links to aggregation of light chains need to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28025584     DOI: 10.1038/leu.2016.387

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  56 in total

1.  A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits.

Authors:  Samsiddhi Bhattacharjee; Preetha Rajaraman; Kevin B Jacobs; William A Wheeler; Beatrice S Melin; Patricia Hartge; Meredith Yeager; Charles C Chung; Stephen J Chanock; Nilanjan Chatterjee
Journal:  Am J Hum Genet       Date:  2012-05-04       Impact factor: 11.025

2.  Genome-wide association study on differentiated thyroid cancer.

Authors:  Aleksandra Köhler; Bowang Chen; Federica Gemignani; Rossella Elisei; Cristina Romei; Gisella Figlioli; Monica Cipollini; Alfonso Cristaudo; Franco Bambi; Per Hoffmann; Stefan Herms; Michal Kalemba; Dorota Kula; Shelley Harris; Peter Broderick; Richard Houlston; Susana Pastor; Ricard Marcos; Antonia Velázquez; Barbara Jarzab; Kari Hemminki; Stefano Landi; Asta Försti
Journal:  J Clin Endocrinol Metab       Date:  2013-07-26       Impact factor: 5.958

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.

Authors:  Niels Weinhold; Tobias Meissner; David C Johnson; Anja Seckinger; Jérôme Moreaux; Asta Försti; Bowang Chen; Jolanta Nickel; Daniel Chubb; Andrew C Rawstron; Chi Doughty; Nasrin B Dahir; Dil B Begum; Kwee Young; Brian A Walker; Per Hoffmann; Marcus M Nöthen; Faith E Davies; Bernard Klein; Hartmut Goldschmidt; Gareth J Morgan; Richard S Houlston; Dirk Hose; Kari Hemminki
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

5.  Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.

Authors:  Jeffrey C Francis; Lorenzo Melchor; James Campbell; Howard Kendrick; Wenbin Wei; Javier Armisen-Garrido; Ioannis Assiotis; Lina Chen; Iwanka Kozarewa; Kerry Fenwick; Amanda Swain; Matthew J Smalley; Christopher J Lord; Alan Ashworth
Journal:  J Pathol       Date:  2015-04-02       Impact factor: 7.996

6.  Inefficient SRP interaction with a nascent chain triggers a mRNA quality control pathway.

Authors:  Andrey L Karamyshev; Anna E Patrick; Zemfira N Karamysheva; Dustin S Griesemer; Henry Hudson; Sandra Tjon-Kon-Sang; IngMarie Nilsson; Hendrik Otto; Qinghua Liu; Sabine Rospert; Gunnar von Heijne; Arthur E Johnson; Philip J Thomas
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

7.  SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.

Authors:  Nicole Vincent Jordan; Aleix Prat; Amy N Abell; Jon S Zawistowski; Noah Sciaky; Olga A Karginova; Bingying Zhou; Brian T Golitz; Charles M Perou; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

8.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

9.  IRF4 is a suppressor of c-Myc induced B cell leukemia.

Authors:  Simanta Pathak; Shibin Ma; Long Trinh; James Eudy; Kay-Uwe Wagner; Shantaram S Joshi; Runqing Lu
Journal:  PLoS One       Date:  2011-07-27       Impact factor: 3.240

10.  Protein phosphatase subunit G5PR is needed for inhibition of B cell receptor-induced apoptosis.

Authors:  Yan Xing; Hideya Igarashi; Xiaodan Wang; Nobuo Sakaguchi
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

View more
  13 in total

1.  Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.

Authors:  Seung-Hyun Jung; Sung-Eun Lee; Minho Lee; So-Hee Kim; Seon-Hee Yim; Tae Woo Kim; Chang-Ki Min; Yeun-Jun Chung
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

Review 2.  Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Authors:  Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2019-01-22

Review 3.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528

4.  Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Authors:  Iman Meziane; Stefanie Huhn; Miguel Inacio da Silva Filho; Niels Weinhold; Chiara Campo; Jolanta Nickel; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Stefano Landi; Jonathan S Mitchell; David Johnson; Anna Jauch; Gareth J Morgan; Richard Houlston; Hartmut Goldschmidt; Paolo Milani; Giampaolo Merlini; Dorota Rowcieno; Philip Hawkins; Ute Hegenbart; Giovanni Palladini; Ashutosh Wechalekar; Asta Försti; Stefan O Schönland; Kari Hemminki
Journal:  Haematologica       Date:  2017-07-04       Impact factor: 9.941

5.  Effects of comprehensive care in patients with multiple myeloma with cardiac dysfunction.

Authors:  Jinglu Xu; Ru Bai
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

6.  Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.

Authors:  Alyssa Clay-Gilmour; Subhayan Chattopadhyay; Celine M Vachon; Kari Hemminki; Michelle A T Hildebrandt; Hauke Thomsen; Niels Weinhold; Pavel Vodicka; Ludmila Vodickova; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Börge Schmidt; Christian Langer; Roman Hajek; Göran Hallmans; Ulrika Pettersson-Kymmer; Claes Ohlsson; Florentin Späth; Richard Houlston; Hartmut Goldschmidt; Elisabet E Manasanch; Aaron Norman; Shaji Kumar; S Vincent Rajkumar; Susan Slager; Asta Försti
Journal:  Blood Cancer J       Date:  2022-04-13       Impact factor: 11.037

7.  Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Authors:  Martin Granzow; Ute Hegenbart; Katrin Hinderhofer; Dirk Hose; Anja Seckinger; Tilmann Bochtler; Kari Hemminki; Hartmut Goldschmidt; Stefan O Schönland; Anna Jauch
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

8.  Breast cancer and amyloid bodies: is there a role for amyloidosis in cancer-cell dormancy?

Authors:  Gerald J Mizejewski
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-04-26

Review 9.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

Review 10.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.